Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.50 indicates a potential upside of 556.2%.The mean estimate comprises six short-term price targets with a standard deviation of $23.86. While the lowest estimate of $3 indicates a 44.6% dec ...